MeSH term
Frequency | Condition_Probility | Antibodies, Monoclonal | 3 | 0.0 |
Antigens, Neoplasm/*analysis | 5 | 1.0 |
Colonoscopy | 2 | 4.0 |
Humans | 79 | 0.0 |
Mucins/*analysis | 2 | 5.0 |
Research Support, Non-U.S. Gov't | 33 | 0.0 |
Risk Factors | 4 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Adult | 28 | 0.0 |
Female | 52 | 0.0 |
Aged | 33 | 0.0 |
Aged, 80 and over | 17 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*blood | 7 | 38.0 |
CA-19-9 Antigen/blood | 3 | 13.0 |
Carcinoembryonic Antigen/blood | 5 | 8.0 |
Gangliosides/*blood | 2 | 66.0 |
Logistic Models | 3 | 0.0 |
Male | 29 | 0.0 |
Middle Aged | 34 | 0.0 |
Oligosaccharides/*blood | 5 | 83.0 |
Predictive Value of Tests | 8 | 0.0 |
Animals | 10 | 0.0 |
Cancer Vaccines/*therapeutic use | 4 | 18.0 |
Clinical Trials | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Survival Rate | 8 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Tumor Markers, Biological | 7 | 1.0 |
Aneuploidy | 4 | 2.0 |
Antigens, Tumor-Associated, Carbohydrate/*analysis | 16 | 55.0 |
Immunohistochemistry | 21 | 0.0 |
Lymphatic Metastasis | 8 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Neoplasm Staging | 9 | 0.0 |
Ploidies | 3 | 1.0 |
Prognosis | 24 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Time Factors | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 17 | 1.0 |
Colorectal Neoplasms/*immunology/*pathology | 2 | 33.0 |
Multivariate Analysis | 4 | 0.0 |
Tumor Markers, Biological/*blood | 10 | 2.0 |
CA-19-9 Antigen/*blood | 4 | 36.0 |
Disease-Free Survival | 4 | 0.0 |
Regression Analysis | 2 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Carbohydrate Sequence | 8 | 2.0 |
Molecular Sequence Data | 12 | 0.0 |
Molecular Structure | 2 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Comparative Study | 8 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*biosynthesis | 6 | 75.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Neoplasm Metastasis | 4 | 0.0 |
Survival Analysis | 8 | 0.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Diagnosis, Differential | 3 | 0.0 |
Carcinoembryonic Antigen/*blood | 2 | 8.0 |
Age Factors | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Colon/pathology | 2 | 4.0 |
Rectum/pathology | 2 | 11.0 |
Serologic Tests | 2 | 2.0 |
Antigens, Tumor-Associated, Carbohydrate/*metabolism | 7 | 36.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*immunology | 3 | 15.0 |
Mice | 5 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/blood | 2 | 13.0 |
Adolescent | 2 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Child | 2 | 0.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Biopsy, Needle | 2 | 0.0 |
Immunization | 2 | 0.0 |
Epitopes | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Antibodies, Neoplasm/immunology | 2 | 5.0 |
Glycosylation | 4 | 0.0 |
CA-15-3 Antigen/*metabolism | 2 | 3.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Mucins/*metabolism | 2 | 2.0 |
Antibody Formation | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*therapeutic use | 2 | 100.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Hemocyanin/*therapeutic use | 3 | 75.0 |
*Immunotherapy, Active | 3 | 12.0 |
Breast Neoplasms/*therapy | 3 | 11.0 |
Colitis, Ulcerative/*immunology/pathology | 2 | 14.0 |
Mucins/*immunology | 6 | 27.0 |
Follow-Up Studies | 2 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Cell Division | 2 | 0.0 |
*Immunotherapy | 2 | 1.0 |
English Abstract | 5 | 0.0 |
Ovarian Neoplasms/*diagnosis | 2 | 16.0 |
Carbohydrate Conformation | 2 | 1.0 |
Complement/immunology | 2 | 2.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Sheep | 2 | 0.0 |
*Antigens, Tumor-Associated, Carbohydrate | 5 | 27.0 |
Carcinoembryonic Antigen/*analysis | 2 | 3.0 |
Carcinoma, Squamous Cell/*immunology/secondary | 2 | 40.0 |
Cervix Neoplasms/*immunology | 2 | 10.0 |
Cervix Uteri/*immunology | 2 | 20.0 |
Lewis Blood-Group System/*analysis | 2 | 28.0 |
